Qiagen N.V. Cash Flow Statement
NYSE: QGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Qiagen N.V. free cash flow
In fiscal 2025, Qiagen N.V. generated $654.3 million of operating cash flow and spent $201.0 million on capital expenditures. That left free cash flow of $453.3 million, a free-cash-flow margin of 21.7% of revenue. Free cash flow was down 10.5% from the prior year's $506.4 million.
Qiagen N.V. returned $334.3 million to shareholders: $54.2 million in dividends and $280.1 million in share repurchases, equal to 74% of free cash flow. Free cash flow covered dividend payments 8.4 times.
Summary generated from market data by MetaCap's automated system. Methodology
Qiagen N.V. cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 424.88M | 83.59M | 341.30M | 423.21M | 512.60M | 359.19M | -41.45M | 190.38M | 40.39M | 80.30M |
| Net Income growth (YoY) | +408.28% | -75.51% | -19.35% | -17.44% | +42.71% | — | -121.77% | +371.31% | -49.70% | -38.18% |
| Depreciation & Amortization | 193.75M | 203.27M | 205.34M | 208.40M | 214.93M | 205.01M | 231.46M | 206.44M | 216.45M | 213.06M |
| Stock-Based Compensation | 50.40M | 43.63M | 47.10M | 49.51M | 38.39M | 40.94M | 65.89M | 40.11M | 34.44M | 28.29M |
| Change in Working Capital | -90.19M | 91.58M | -177.22M | -68.12M | -165.46M | -135.67M | -41.85M | -115.37M | -65.44M | -19.88M |
| Operating Cash Flow | 654.33M | 673.55M | 459.45M | 715.26M | 639.00M | 457.81M | 330.84M | 359.50M | 286.78M | 341.60M |
| Capital Expenditures | -201.05M | -167.17M | -149.71M | -129.22M | -189.90M | -132.79M | -117.95M | -109.77M | -90.08M | -74.54M |
| Investing Cash Flow | -305.28M | -249.23M | -87.66M | -726.76M | -202.43M | -443.28M | -222.28M | -211.36M | -464.26M | -179.06M |
| Dividends Paid | -54.24M | 0 | 0 | — | — | — | — | — | — | — |
| Share Repurchases | -280.09M | -292.10M | 0 | 0 | -99.99M | -63.99M | -74.45M | -104.69M | -60.97M | 0 |
| Debt Issued | 742.32M | 494.21M | 0 | 371.45M | 0 | 497.65M | 0 | 0 | 329.88M | 0 |
| Debt Repaid | -534.17M | -601.54M | -400.00M | -480.00M | -41.34M | -296.40M | -506.40M | 0 | 0 | -6.74M |
| Financing Cash Flow | -178.98M | -422.90M | -433.83M | -125.80M | -150.37M | -50.13M | -639.08M | 360.41M | 387.19M | -10.60M |
| Net Change in Cash | 175.45M | -4.53M | -62.59M | -149.85M | 282.53M | -31.41M | -529.69M | 501.37M | 218.53M | 149.17M |
| Free Cash Flow | 453.28M | 506.38M | 309.75M | 586.04M | 449.10M | 325.02M | 212.89M | 249.72M | 196.70M | 267.07M |
This table shows 10 annual periods of Qiagen N.V.'s cash flow statement, from FY 2025 back to FY 2016, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow QGEN's reporting calendar. What is a cash flow statement?